Vanda Pharmaceuticals said Wednesday it is putting its social anxiety disorder program on hold following a late-stage trial failure.
The biotech’s drug, called VQW-765,
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.